Amneal Pharmaceuticals reported net revenue of $862.7 million for the third quarter of 2026, an increase from $784.5 million in the prior year period. Despite higher operating income, the company recorded a net loss attributable to Class A common stockholders of $21.7 million for the quarter, primarily due to accretion of redeemable non-controlling interests and acquisition-related costs.
Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million, a 10% increase year-over-year, driven by strong growth in biosimilars and specialty products. Despite the revenue growth, the company posted a GAAP net loss of $22 million due to acquisition and integration costs related to Kashiv. Consequently, Amneal raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.
Term
Q3 2026
“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector.”
Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers
Amneal Pharmaceuticals M&A Deal with Kashiv BioSciences, LLC
Amneal Pharmaceuticals filed an amendment to its previous 8-K to provide required historical financial statements and pro forma financial information following its completed acquisition of Kashiv BioSciences, LLC. The acquisition was originally completed on August 10, 2026, pursuant to a Membership Interest Purchase Agreement dated April 21, 2026.